newsfilter
← Latest News
GlobeNewswire·

PharmaTher Holdings Submits FDA Meeting Package to Discuss Phase 3 Program and Fast Track Designation for KETARX™ (Ketamine) in Parkinson's Disease

TORONTO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the "Company" or "PharmaTher") (OTCQB:PHRRF) (CSE:PHRM), a leader in advancing specialty ketamine pharmaceuticals, today submitted its meeting